Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine (Q35143220)

6 August 2017

1 reference

title

Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine (English)

1 reference

6 August 2017

main subject

evidence-based medicine

1 reference

Stephen G Ball

1

1 reference

6 August 2017

William B White

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

American Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

91

1 reference

6 August 2017

issue

10A

1 reference

6 August 2017

page(s)

15G-21G

1 reference

Effect of age and disease on two drug binding proteins: Albumin and α-1-acid glycoprotein

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

The role of the renin-angiotensin system in the development of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Cardiovascular protection and blood pressure reduction: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Blood-pressure reduction and cardiovascular risk in HOPE study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Chymase-dependent angiotensin II forming systems in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Angiotensin II receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900228-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(03)00228-5

1 reference

6 August 2017

1 reference